Analysis

Wuxi Biologics (cayman) Inc. (2269) Stock Analysis

Wuxi Biologics (cayman) Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to 2269.

website2269/analysis/2269

Wuxi Biologics (cayman) Inc.

Wuxi Biologics (cayman) Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to 2269.

Stock profile

Ticker

2269

Asset type

Stock

Market cap

$16.29B

Sector

Health Technology

Industry

Biotechnology

Currency

HKD

Ticker listings

Wuxi Biologics (cayman) Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • 2269 primary listing
  • 1FW2
  • WUXI06
  • WXXWY
  • WXIBF
  • WUXI13
  • A2QJCN
  • 1FW1

Latest Wuxi Biologics (cayman) Inc. news

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European M...

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has succe...

WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellen...

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Pro...

WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year

WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities

WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product

Research sections

Valuation

Review valuation context for Wuxi Biologics (cayman) Inc..

Future growth

Review future growth context for Wuxi Biologics (cayman) Inc..

Past performance

Review past performance context for Wuxi Biologics (cayman) Inc..

Financial health

Review financial health context for Wuxi Biologics (cayman) Inc..

Dividend

Review dividend context for Wuxi Biologics (cayman) Inc..

Management

Review management context for Wuxi Biologics (cayman) Inc..

Ownership

Review ownership context for Wuxi Biologics (cayman) Inc..

Other information

Review other information context for Wuxi Biologics (cayman) Inc..

Community

Review community context for Wuxi Biologics (cayman) Inc..